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Abstract--We propose a mathematical modelization and optimization of the action of 
some drugs such as 13-blockers--a particular drug (tertatolol) studied in Servier labo- 
ratories is specially examined. Linear compartmental models are first tried but they are 
not convenient for explaining the experimental data. Then a dose effect relation is 
directly seeked. One obtains a nonlinear elationship between the dose, the plasmatic 
concentration and the drug's effect. Using some optimal control methods allows one 
to define an optimal therapeutic giving the optimal doses and possibly the optimal times 
optimizing some given criteria. 
1. INTRODUCTION 
The [3-blockers are used for the treatment of cardiac disorders[l] (hypertension, angina 
pectoris, cardiac arrhythmias). The medical effects are well proved[2]. Our study consists 
first to relate the blood concentration of such drugs and the medical effect. The main 
difficulty comes from the nonlinearity of the phenomenon. After obtaining a well-adapted 
mathematical model it becomes possible to solve optimal control problems involving op- 
timal therapeutics (indeed we can find the optimal oral doses and the optimal times of 
injection). The experimental results are given by Servier laboratories (cardiologic division) 
and are relative to a drug called Tertatolol. A compartmental classical approach[3] was 
first used and allowed to prove the nonlinearity of the biological system. Then a "black 
box"  study was proposed for obtaining a convenient mathematical relation between blood 
concentration of drug and pharmacodynamic effect. The associated optimal control prob- 
lem may be solved numerically by using an original global optimization method[4] de- 
veloped in Medimat laboratory. 
2. CLASSICAL APPROACHES FOR MODELL ING THE DRUG'S EFFECT 
Classical literature[5] generally proposes simple linear relationships uch as the 
following: 
E = a logC + b, (2.1) 
where C represents the concentration of drug in blood and E the effect. In the case of 
tertatolol, the effect is the product of the arterial pressure by the heart rate. The formula 
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(2. I) involves two constants a and b which have to be identified from experimental data. 
Table 1 gives experimental data performed with ten volunteers in good health. Table 1 
gives the mean values. For each patient, the plasma concentration C and the effect E was 
measured at various times ti: 
ti = O, 0.5, I, 2, 4, 6, 9, 12, 15, 24 h, 
and for four doses, 
D = 1 ,2 .5 ,  10mg. 
Unfortunately it was not possible to identify a and b [in (2. I)] satisfying the experimental 
data and the relationship (2.1). Therefore, the relationship between the effect E and the 
log C is not linear. Later we shall propose a nonlinear approximation generalizing (2.1). 
But before we must notice the drug's efficiency proved by the following results: 
• The efficiency is an increasing function of the absorbed ose; 
• the individual means of E are decreasing functions of the dose: 
• the individual differences between the maximum and the minimum values of E are 
increasing functions of the dose. 
Now coming back to the problem of finding a mathematical relation between the con- 
centration and the effect, one can propose a natural generalisation of formula (2. I) such 
as the following: 
E = bo + a~ log(l + C) + a21og'-(1 + C). (2.2) 
With the experimental data given by Table 1, we obtain (for D = 2 mg) at = -22.2017, 
a_, = 0.756 14 . . .  and a good approximation of the effect[8]. In (2.2) bo is a constant 
depending on the individual. Of course this formula proves the nonlinearity of the 
relationship. 
Another classical approach[6, 7] was also tried. It is based on the compartmental n- 
alysis[8] and consists to relate our variables by a three compartments model such as in 
Fig. 1. 
Such a linear model leads to the following structural expression for the blood concen- 
tration of drug C~(t): 
C~ = ao e-X°' + a~ e -~"  + a2 e-~-" (?,i -> 0). (2.3) 
Table I. 
Doses 1 mg 2 mg 5 mg 10 mg 
Times 
(in hours) C E C E C E C E 
0 0 28.5 0 26.1 0 24.5 0 25.4 
I/'2 7.7 25.5 28.9 21.3 58.5 19.0 150 17 
1 15.6 22.6 32.3 18.7 88.9 15.9 190.4 14.2 
20 20 32.5 17 I 11.4 14.5 197.9 13.8 
4 I1.1 21.2 22.1 17.3 71.6 14.7 116 14.4 
6 5.7 23.9 11.7 20.5 38.2 16.1 66.5 16.4 
9 1.4 24.6 5.2 21.3 20.7 17.7 33.5 16.3 
12 0.3 25.5 2.6 __.6 10.9 18.1 20.5 17.9 
15 0.15 25.9 0.8 24.8 5.2 20.3 11.7 19.4 
24 0 26.4 0.3 23.2 2 20.8 5.2 20.1 
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Identifying the a: and Xi (i = 0, 1. 2) involves characteristic values ~., depending on the 
dose D (see Table 2). Furthermore, the parameters ai are not proportional to the dose. 
All these facts involve the nonlinearity of the model[3. 8, 1]. The conclusions were the 
same when examining the 40 series of individual values. 
Therefore, a linear compartmental model may not be adapted to our drug (tertatolol). 
Formula (2.2) could be retained with some improvements. Indeed the coefficients at 
and a: depend on D. Furthermore, (2.2) gives a poor approximation between 15 and 24 
h. A delay has to be introduced in our model. Thus we prefered to build directly a re- 
lationship between the dose D, the plasmatic oncentration C and the effect E. To do that 
a nonlinear generalization of (2.1) was imagined and the following relation was proposed: 
E = bo + bl log{l + C[':D(t)]}, (2.4) 
where bo is a constant depending on individual; b~ has to be identified as well as the 
function yo(t) that plays the role of a delay function. Practically. C is taken as 
C = a~ e -x ' t  + ae e-~' - ' t  (k t ,  k2 t> 0). (2.5) 
where aK, a2, at,  h: are identified from the results corresponding to the dose D = 2 mg 
by minimizing the criterion 
a l  .a2 . ,k l  ,K2 j=  I i=  I 
(2.6) 
where C(tj) represents the experimental data (concentrations) associated to D = 2 mg. 
The global optimum of this criterion was obtained by using a global optimization technique 
that will be described later. The main difficulty comes from the identification of yo(t).  
Table 2. 
8% 
Doses ;% M h.- ao a~ a_~ fstandard eviation) 
I mg 1.633 39 1.383 01 0.427 67 193.492 -265.72 68.405 3.496% 
2 mg 6.8834 0.4855 0.426 34 -20.733 -468.45 491.37 3.6018% 
5 mg 0.730 083 0.574 84 0.139 29 - 1079.47 1011.89 50.29 4.9063% 
10 mg 1.331 95 0.717 82 0.220 II -532.247 282.208 249.663 4.449% 
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We tried three possibilities for ",/: 
• a linear function according to t, 
• a quadratic polynomial function, 
• a cubic polynomial function. 
The general structure used for "/o(t) was thus the following: 
rn  
"/o(t) = ~, akt k (where m = I. 2 or 3). (2.7) 
k=l 
The parameter b~ is determined independently of D. But the coefficients of "yD(t) in (2.7) 
are identified in function of the dose D (in fact polynomial functions of degree 3 were 
identified). 
More precisely, the following optimization problem has to be solved: 
IO 
min ~ (bo + bj log{1 + C['/o(t)]} - E(tj, D)) 2 (2.8) 
b l ,a l  . . . . .  am j= I 
for each dose D. Of course ~D(t) is replaced in (2.8) by its mathematical expression (2.7). 
Then the functions ak(D) in (2.7) are identified by using once more an optimization 
technique[9]. 
The mathematical relation (2.4) being completely identified, it becomes possible to 
consider the important problem of defining an optimal therapeutics relative to some op- 
timal criterion. 
3. OPTIMAL THERAPEUTICS- -A  FIRST APPROACH USING A L INEAR 
MODEL 
The main objective of a medical treatment consists in optimizing therapeutics. In other 
words we need to maintain the effect E approximately constant. According to the formulae 
(2.2) or (2.4) this problem is equivalent o the following: 
Maintain the concentration C equal to a constant as far as possible. In other words the 
criterion 
f0 T J = [C(t) - A] 2 dr, where A is a fixed constant, (3.1) 
has to be minimized. In (3.1) the constant A is determined from medical considerations. 
For each dose, the function C (noted Ci in the following) may be considered in first 
(and rough) approximation as the solution of the three compartments model described in 
Fig. 1 and represented by the differential linear system 
Co = - k~Co,  
Ci = - (kl,. + ke)Ci + k21C2 + k~Co(t), 
Cz  = kt,_Cl  - k,_lC,_, (3.2) 
Ct(0) = 0, Cz(O) = O, 
Co(0) = C 'e related to D(= D/Vt ,  Vi volume of compartment I). 
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Of course, Ct ( t )  is the solution of the following system: 
Ct  = -- (k12 + k~)Cl + k21C,  + t t ( t ) ,  
C2 = k tzCt  - kztC:_,  (3.3) 
Cl(O) = C2(0) = O, 
where u(t) = kaCo(t)  = (Dka/V~) e -k"t is an input function coming in compartment 1.
u(t)  may be considered as the control function and thus a first question arises: What is 
the optimal function u(t)  ensuring 
The answer is very easy, It suffices to consider first the case where the initial conditions 
in (3.3) are Ct(0) --- A,  C2(0) = 0. Putting C~(t) =- A (for all t /> 0) in (3.3) involves 
C._ = kl,_A - kztC2, 
giving easily 
C, ( t )  = - (kl2/k21) [A e-k ' - "  _ A] .  (3.5) 
Then the first equation (3.3) leads to 
u(t)  = A[ke  + kl2 e-k:"] .  (3.6) 
More generally, if we consider the general initial conditions 
Cl(0) = C2(0) = 0, (3.7) 
the Laplace transformation[t0] allows to find a general solution which is a distribution 
function[10]. Indeed the optimal control given by (3.6) becomes 
u(t) = A[8(o~ + k~, + kl2 e-k-'"], (3.8) 
where 8t0~ is the Dirac function[10] corresponding practically to an instantaneous injection 
at time 0. The relationship (3.8) can be easily proved by transforming (3.3) with the Laplace 
transformation. 
The optimal control problem (3.4) associated to the differential system (3.3) being solved 
(explicitly[) the general problem (3.2), (3.4) may be considered. The idea consists to find 
an optimal solution corresponding to oral doses D,- (i = 0 . . . . .  m) given at times ti and 
approximating the optimal controls (3.6) or (3.8). More precisely, the doses Di and times 
ti have to be determined for ensuring the minimization of the criterion 
J, = (jor ~ D ik~ e -k°" - '~ 'Y ( t  - tfl - Ake - Ak ,2  dt, (3.9) 
j=O 
where Djk .  e -ko(,-, j~ corresponds to an input ui(t) in compartment 1 associated to an oral 
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dose Di taken at time ti. The function Y(t - tj) is the Heaviside function equals to 0 for 
(t - t s) < 0 and equals to 1 for (t - ts) >t O. The criterion (3.9) has to be minimized 
according to the parameters Do . . . . .  Din. to, t~ . . . . .  t , , .  The sum in (3.9) takes into 
account he following hypothesis: 
• when successive doses are absorbed the corresponding concentrations of drug must be 
added. The term 
m 
~,  D ik ,  e -k , " - ' , ' y ( t  _ ts) 
j=0  
is thus the resulting concentration when (m + 1) doses D s are absorbed at time t s. This 
hypothesis i in agreement with the classical parmacologic literature[1 l, 12]. This opti- 
mization problem (3.9) is equivalent to that of finding the "best" doses and times giving 
the best approximation of the exact optimal solution 
Ake + Ak l2  e- I"- ' t  
Numerical results were performed with A = 7.383 426 (biological constant determined 
by medical considerations) corresponding to an effect E = 20. The follo~ving optimal 
results were obtained for T = 24 hr: 
to = 0, Do = 1.013 mg, Dz = 3.168, tl = 16.74. 
As we shall see later, these numerical results are not very different of those obtained by 
using nonlinear models. 
4. OPTIMAL THERAPEUTICS ASSOCIATED TO NONLINEAR MODELS 
Recall the formula relating the dose, the concentration and the effect of the drug 
(tertatolol): 
E = bo + b~ log[1 + C(yo( t ) ] .  (4.1) 
We are now working with identified parameter b~ and function yo( t ) .  Optimal therapeutics 
may be determined by setting the following optimal control problem: Find the inputs 
(doses) Do . . . . .  Dj and the times of absorption to . . . . .  tj such that the criterion 
fo r [E(t) - 20] 2 dt (4.2) 
be minimum. The constant 20 (and later 19) is an effect value defined by biological con- 
siderations and corresponding to a satisfactory value of the effect. The time T is fixed 
and may be great. Of course, it will be necessary to precise the function E(t )  in presence 
of successive doses Di absorbed at times t,-. 
Using the additivity of the concentrations when successive doses are given and fixing 
first the times ti and the number of doses j + 1, we obtain the simplified optimization 
problem: 
/ 
min / [E ( t ) -  2012dt = rain ~ / [E,-(t)- 2012dt. (4.3) 
Do . . . . .  D j  JO  Do  . . . . .  D j  i=0  "lti 
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where the funct ion Eg(t) introduced in (4.3) is defined by 
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i 
Ei(t) = bo + bl log 1 + 
k=i - I  
C[~/o,(t - 24k) lY ( t  - 24k)) , (4.4) 
with t ~ (t~, ti+l), and where we use only the two last terms of concentrat ions corre- 
sponding to the doses D~ and Di_ i. This approximation is justified by the experimental 
data: The concentrat ions are weak after 24 h following the absorption. If we want to 
consider all the concentrat ions,  the formula (4.4) becomes 
E~(t) = bo + b l log  1 + C[yDAt  - 24k)]Y(t  - 24k) . (4.5) 
Of course it is easy to generalize to an arbitrary time interval 13 # 24. Instead of supposing 
the concentrat ions additivity it is possible to introduce the additivity of  effects which 
involves a new formula for E~(t), effect on (t~, t~, 1): 
i 
Ei(t) = bo + ~ b, Iog{l + C[~lD~(t - 13k)1}, (4.6) 
k=0 
where 13 is the interval between two successive times ti, t i -  ~. Decomposit ions similar to 
those used in dynamic programming[13] can be developed. We obtain 
j . t i+  I 
rain __~of ' (E i -  20) :d t  
Do . . . . .  D j  i=  i 
[so ; ] = min (Eo - 20) zdt  + ... + min (E i - 20) :dr  , (4.7) Do . . . . .  D i  - I Oi t 
because in the first sum all terms but the last are independent of Dj. In the same way we 
deduce 
min 
Do . . . . .  D j -  I [;o ; ] (Eo - 20) 2 dt + ... + min (Ej - 20) 2 dt Oi  I 
= min (Eo - 20)-" dt + ... + rain (Ej_~ - 20): dt 
Do . . . . .  D j  - 2 D i  - I i - I 
+ min j  (Ej - 20)-" dt . 
D i ti 
(4.8) 
This relation is obtained because only the two last terms on the right-hand side are de- 
pendent of  Dj_ ~. The process is cont inued until 
min 
Do . . . . .  D j  i = 0 t, 
(E l -  20) 2 dt = min 
Do 
(Eo - 20) 2 dt + min (E~ - 20): dt 
DI  t l  
( ;  ) 1) + ... + rain (Ej - 20) 2 dt ... . (4.9) l 
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Then a numerical algorithm may be proposed: 
• At step 0 f~J+' (Ej - 20) 2 dt is minimized according to Dj for different values of D~_ 
(practically I, 2, 5, 10 mg). The function Dj is thus identified using a fixed mathematical 
structure such as the following: 
D i = d~o(Dj-t) = Aj  e x '° ' - '  + A2 e x-'°'-'. (4. I 0) 
• At step j, the following sum is minimized according to the single variable Do: 
min[  fo" oo 
f t  t2 (Eo - 20)-" dt + {Et [Do, cbj_,(Do)] - 20}-" dt 
I 
;/ ] + ..- + {Ej[d~,(D~_2), ~bo(Dj_,)] - 20}2 dt . (4.11) 
Do being determined, we can define successively Dt . . . . .  Dj by using the following 
relations: 
D, = cbj_t(Do), Dz = daj_2(D,) . . . . .  Dj-= d0o(Di_,). (4.12) 
Numerical results based on this technique will be detailed in the next paragraph. 
The previous method was well adapted to the particular optimal problem where the 
times of absorption were fixed. Now we will treat the general  problem consisting in finding 
the doses D~ and the times ts. More precisely we want to solve 
min J [E ( t ) -  19]'-dt = min --~o f '  
Do . . . . .  Dm 0 Do  . . . . .  Dm i= i 
l 0 . . . . .  ln l  l" 0 . . . . .  I t ,  t 
[Eg(t) - 19]-" dt. (4.13) 
where the biological constant is chosen equal to 19 and where the effect Ei(t) on [ti, t , - j ]  
is defined by the formula 
{ i } 
Ei(t) = bo + bl log I + ~ C[yD,(t -- 13k)] , (4.14) 
k=0 
using the additivity of concentrations. A numerical algorithm giving only a subopt imum 
may be performed as follows: 
• At step 0 the following optimization problem is solved: 
t l  
min f (Eo - 19) 2 dt, (4.15) 
Do, to o 
where t6 and tl are fixed (for instance t6 = to = 0, t] = 24 h). Let Do and to the optimal 
calculated solutions. 
• At step k we need to solve the optimization problem 
t -  
min / (E~-I - 19) 2 dt, (4.16) 
Ok-  I ..J t t ,  - i 
with t~- fixed (for instance t~: = 24 k). 
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Solving this problem for several values &:_ i allows to find the relation Dk- 1 = ~(t~:_ I). 
In fact we may look for a fixed formula such as 
Dk-t  = a~ e x'ta-' + a, e ~'zr~ ' = d:)(t~:-i), (4.17) 
where a~, a._, M, ~.2 are identified with an optimization technique[14, 15]. 
• Then at step kb~s we consider the optimization problem 
min ;_, (Ek-2 - 19)" dt + (Ek-~ - 19): dt , 
g'k--I k - - I  
(4.18) 
where t~-_ i, ti: are fixed (for instance we chose t~. = 24 k). Using a numerical optimization 
algorithm[19] gives tk-~. Indeed the function in (4.18) depends only on tk-~ by putting 
the expression (4.17) [Dk-i  = d~(tk-~)] in the formula (4.14) giving E~(t) in function of 
D~. Numerical experiences will be given later. Before we shall describe a new global 
minimization technique which will be applied to our optimal therapeutics problems. 
5. A GLOBAL OPTIMIZATION METHOD FOR SOLVING OPTIMAL 
THERAPEUTICS  PROBLEMS 
Let us consider the general optimization problem introduced in the previous paragraph: 
1" 
rain f 
Do . . . . .  D,,~ ) 
tt  . . . . .  tm 
[E(t) - L]: dt, (5.1) 
with the contraints 0 ~< Dj ~< 10, 24j ~< ti ~< 24(j + l ) , j  = I . . . . .  rn. in (5.1) the constant 
L may be arbitrary (for instance equal to 19 or 20 or to any "'optimal" value defined by 
the physician). The formula associated to E(t)  on [0, T] with successive doses at time t~ 
may be defined as follows: 
( i ) 
Ei(t)  = bo + b, log 1 + ~ C(yD~, t - tDY( t  - tk) 
k=O 
(5.2) 
on (t,-, tic-i). 
This relation uses the additivity of the plasmatic oncentrations. In practical problems 
coming for instance from pharmacodynamics and needing minimization or maximization 
methods, only the absolute extremum can supply the best result, i.e. the best solution of 
our optimal control problem. Thus a method giving this value would be very important 
and interesting. Unfortunately, the classical iterature does not supply many techniques 
in this area outside of the case involving one-variable functions. Our idea[16] consists to 
transform the n-variables functions into a one variable function. To do that we use a 
simple transformation called Alienor[4] and based on the property of the Archimedian 
spiral (r = a0). The curve representing the spiral lies at a maximum distance (2"rra) from 
any point M in the space R 2. 
Then let us consider an optimization problem: 
min f(x, y). (5.3) 
. r , y  
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Setting x = a0 cos 0, y = a0 sin 0, 0 I> 0, involves 
min f(x, y) ~ rain f(aO cos 0, a0 sin 0) = rain G(0), 
0 0 
(5.4) 
leading to a one-variable minimization problem. 
This transformation can easily be generalized to n variables giving a tree structure[ 17]. 
From an optimal point 0 the coordinates x, y may be calculated by using x = a0 cos 0, 
v = a0 sin 0 and conversely if we want to obtain 0 in function of x. y we have 
0 = (I/a) N/x-" + y2. (5.5) 
Generalization to n variables does not present any difficulty. 
Let us now apply the Alienor transformation to the problem (5.1) with, for instance, 
five variables t~, t_,, Do, D~, D:. The following transformations have to be performed: 
t~ = (0: cos 0,_)/2v, t,_ = (0,. sin 0_,)/2v, Do = (03 cos 03)/2w, 
D~ = (03 sin 03)/2~', D: = (04 cos 0~)/2v, 
where a is chosen equal to 1/2~r[17]. Then 
0o = (0 cos 0)/2w, 0~ = (0 sin 0)/2"rr, 02 = (0o cos 0o)/2~r, 
03 = (% sin 0o)/2v, 0a = (0~ cos 0~)/2w. 
We note that one obtains a unique variable 0 involving a new optimization problem 
according to the single variable 0. It suffices to explicit the functional 
fo r [E(t) - L] 2 dt 
in function of 0. 
For obtaining this dependence the parameters tt, t2 . . . . .  D2 have to be expressed in 
function of 0 by using the previous transformation. Numerical experiences will be de- 
scribed in the following. Some crafts are necessary for accelerating the numerical pro- 
cess[17]. For complementary informations one can consult [17]. 
Remark. Some other classical optimization techniques were also tested[18]. For in- 
stance, we used the Vignes's method[19, 20] which is a variant of the Hooke and Jeeves 
method[9]. The main inconvenience of these techniques i that they give a local optimum 
and we are never sure to obtain a global optimum. Furthermore, they need the derivability 
of the function to optimize. On the contrary our global method needs only the continuity. 
And even the continuity is not necessary! Of course this global method can be used for 
many biological problems involving some criterion optimization[21,22] and even for solv- 
ing functional equations. 
6. A LAST METHOD BASED ON A NON L INEAR RELATION 
In the previous parts we detailed some methods using optimization or dynamic pro- 
gramming techniques. These methods allow to determine optimal therapeutics when oral 
multiple doses are considered. In the present approach we propose to use directly the 
concentration i the blood compartment and to generalize the third paragraph where a 
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linear compartmental model was considered. Indeed concentrations in blood compartment 
1 (Fig. I) may be used in place of E because we built a functional relation between E and 
C, that is to say 
E = bo + bl log{l + C[yolt)]},  (6.1) 
where the constant bj and the function yD(t) was identified from experimental data (Table 
I). 
From (6,1), E = 19 involves the concentration A = 11.8264. Then our optimal ther- 
apeutic problem may be set as follows: Find the doses De and the times of absorption ti
such that 
fo T [C(t )  - A] 2 dt (6.2) 
be minimized (i = 1 . . . . .  m). The main difficulty consists to precise C(t) on [0, T]. 
It is possible by introducing a nonl inear compartmental model in which C(t) is described 
by the formula: 
3 
C(t, D) = ~ ai(D) exp[hi(D)t]. 
i=1 
(6.3) 
Unlike the linear compartmental models, the mathematical expression (6.3) involves pa- 
rameters X,- depending on the dose D. A nonlinear model with three compartments may 
be associated to (6.3). It involves exchange parameters k u depending on D. In (6.3) the 
coefficients ae and Xe are unknown and must be identified as functions of D by using 
optimization techniques[23]. Then we can precise the function C(t) appearing in (6.2). 
Let us set 
rrt 
C(t) = ~ Y(t - h)C(De, t - tel  (6.4) 
i=1 
where Y(t) is the Heaviside function previously defined and where C(D, t) is expressed 
by (6.3). 
The definition (6.4) results from the additivity of plasmatic oncentrations. Setting 
m 
u(t) = ~ DiB(t,), (6.5) 
e=l  
where B~,,~ is the Dirac mass at time ti, the optimal control problem (6.2) becomes 
~0 T min [C(t) - A] 2 dt, (6.6) 
u(t) 
with C(t)  given by (6.4). More precisely we must solve 
( _ Y(t - ti)C(De, t - te) - dt, min 
DI  ,gl . . . . .  Dm.t rn  JO  e= I 
(._ aj(Dj) exp[hi(De)(t - ti)] Y(t - h) - rain 
DI  , t l  . . . . .  Ore . t in  .10  i=  1 j=  I 
dt. 
(6.7) 
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Direct optimization techniques may be used for solving (6.7). Of course, the Nobal method 
may be performed without any difficulty because the unknowns appears in an explicit 
manner. 
Remark. A variant of this technique consists to propose a model described by a non 
linear differential system. Then for minimizing 
fo r [C(t) - A] 2 dt, 
we decompose the interval [0, T] into subintervals [ti, ti-1] in which the differential system 
is linearized. On each interval (ti, ti+ I) the following criterion: 
ff +' [C(t) - A] 2 dt i 
is minimized according to the a control u(t), input function in the blood compartment.  
The using of the explicit method valid for linear compartmental  models allows (Sec. 2) 
to find an exact, explicit, optimal solution u(t) on each interval (t,-, t,-, i). Recall that the 
optimal solution is obtained with the Laplace transformation. 
7. NUMERICAL  RESULTS 
Alienor or Vignes techniques were used for the parameters identification of models. 
When integrals appear, they are approximated with the midpoint or Gaussian formulae[24]. 
(a) The dose effect relation 
E = bo + bl log{1 + C[yo(t)]} 
was identified. First we chose 
C = al e x'r + a2 e x-'t, 
where the parameters a~, a2, hi, h.2 were calculated by the Vignes's method. One obtained 
al = -a2  = -54.437, M = -1.918,  h2 = -0.246.  
After several attempts we chose a cubic polynomial approximation for "¢o(t). Setting 
"Co(t) = i=, ~ Q=~ CijD4-J) ti' E = (%),  
an optimization technique gives the following identified parameters e,7:. 
E = 
9.982 17E - 04 -0 .019 291 9 0.148 249 
4.75232E - 04 -4 .08883E - 03 -0 .024962 1 
-2.551 01E - 05 2.549 12E - 04 5.418 93E - 04 
with bo = 25. b, was equal to -2 .687 578 62 
(7.1) 
0.189 783'~ 
0.236 936 / , 
-0 .008 267// 
(7.2) 
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Tab le  3 a l lows to compare  the ca lcu la ted  effects E,. to the exper imenta l  measured  effects 
Eexp • 
Note  that a l inear  approx imat ion  for ~/o(t) as funct ion  of  t is still conven ient .  Th is  
approx imat ion  will be reta ined for the next  ca lcu lus .  
(b) The  dynamic  programming techn ique[6]  was appl ied for f inding the opt imum of  
min  (Ei - 20)-" dt, 
DO . . . . .  D j  i=1  i 
(7.3) 
with t i* ,  - ti = 24 h, to = 0. The  ca lcu la ted  opt imal  doses were the fo l lowing:  
Do = 4.69, DI = 4.53, D,_ = 4.52, D3 = 4.67, (7.4) 
with 
to = 0, t~ = 24 h, t2 = 48 h, t3 = 72 h. 
(c) The  genera l  p rob lem was t reated with the a lgor i thm giv ing a subopt imum.  The  
opt imal  doses  and  t imes are 
Do = 5.895, to = 0, D~ = 5.69, t~ = 28 h. 
(d) The  g lobal  opt imizat ion  techn ique  (A l ienor)  was per fo rmed for the prob lem:  
. T  
rain Jo 
DO . . . . .  D j  
II . . . . .  t j  
to=O 
[E(t)  - L] z dt. (7.5) 
• j = 2, T = 72 h, L = 19 invo lve  
Do = 8.07, to = 0, D~ = 1, t~ = 38 .69h ,  D2 = 5.3, t2 = 51 .84h .  
• For j  = 2, T = 72, L = 20 in (7.5) one obta ins  
Do = 6.895, to = 0, D,  = 1, t, = 43.56, De = I, t2 = 58.89, 
Table 3. 
Doses 1 mg 2 mg 5 mg 10 mg 
Time 
(in hours) E~xp E~ E~p Ec E~p E, E~p Ec 
0 28.5 28.5 26.1 26.1 24.5 24.5 25.4 25.4 
0.5 25.5 25.64 21.3 21.18 19 18.26 17 18.05 
1 22.6 21.81 18.7 18.64 15.9 16.58 14.2 16.69 
2 20 19.2 17 16.71 14.5 15.21 13.8 15.84 
4 21.2 19.43 17.3 16.98 14.7 14.97 14.4 16.05 
6 23.9 21.22 20.5 18.58 16.1 15.75 16.4 16.85 
9 24.6 24.31 21.3 21.35 17.7 17.29 16.3 18.13 
12 25.5 26.66 22.6 23.62 18.1 18.84 17.9 19.1 
15 25.9 27.72 24.8 24.84 20.3 20.12 19.4 19.53 
24 26.4 26.18 23.2 23.12 20.8 20.77 20.1 20.05 
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other numerical results are available in technical reports of Medimat and Servier 
laboratories. 
8. CONCLUSIONS 
Some mathematical nd numerical techniques were presented for studying the obtention 
of optimal therapeutics when a dose effect model can be previously established. The 
classical iterature gives some attempts in this direction but generally only in the linear 
case. 
In [15] Sheiner proposed functional forms for structural biological models. He suggested 
polynomial, exponential or Hill functions. The logarithmic form was forgotten in spite of 
its good adaptation to biological systems. 
Furthermore, [12], [25] and [26] give simple linear pharmacokinetic models used for 
identifying the pharmacokinetic parameters or for determining input doses. Our present 
work is devoted to the modelling of non linear kinetics (non linear dose-effect relations) 
and to the resolution of the associated optimal control problems involving optimal ther- 
apeutics. By this way we showed that the drug's action can be optimized. In [27] Swan 
described optimal control problems related to the optimal administration of drugs. He 
obtained some explicit solutions for linear compartmental models involving two or three 
compartments. The using of dynamic programming and conjugate gradient methods are 
also considered. But no nonlinear problem was considered. On the contrary our work 
proposes a theory for optimizing the drugs' effect when the relationships are nonlinear 
(coming in particular from nonlinear compartmental models). Furthermore, we used clas- 
sical optimization techniques[28] for solving optimal control problems associated to our 
nonlinear models. But an original global optimization method was also tested. One can 
see that the numerical results are quite identical. Moreover, they are in a~eement with 
the physicians' experience. The practical consequences of the mathematical study of 
tertatolol are the following: 
• A dose of about 5 mg per day (24 h) is quite optimal; 
• if the absorption is early (or late) around optimal times, there are few consequences 
on the effect. 
Introducing optimal control methods in pharmacokinetics and pharmacodynamics lead 
to an improvement of therapeutics and can bring a theoritical justification to clinical 
investigations. 
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